Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
26.61
-0.61 (-2.24%)
Dec 27, 2024, 4:00 PM EST - Market closed
Zai Lab Revenue
Zai Lab had revenue of $102.27M in the quarter ending September 30, 2024, with 47.72% growth. This brings the company's revenue in the last twelve months to $355.75M, up 35.01% year-over-year. In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth.
Revenue (ttm)
$355.75M
Revenue Growth
+35.01%
P/S Ratio
7.30
Revenue / Employee
$163,562
Employees
2,175
Market Cap
2.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ZLAB News
- 3 days ago - Zai Lab: Rapidly Improving Outlook Bodes Well For The Future - Seeking Alpha
- 17 days ago - Zai Lab Announces Participation in Investor Conference in January 2025 - Business Wire
- 27 days ago - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire
- 4 weeks ago - Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List - Business Wire
- 5 weeks ago - Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) - Business Wire
- 5 weeks ago - Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - Business Wire
- 6 weeks ago - Zai Lab Announces Pricing of Public Offering of American Depositary Shares - Business Wire
- 6 weeks ago - Zai Lab Announces Proposed Public Offering of American Depositary Shares - Business Wire